LeMaitre Vascular, Inc. — 2023 Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2023; it is an annual report, not a standalone fourth-quarter filing. LeMaitre develops, manufactures and sells vascular medical devices and provides human-tissue cryopreservation services. It sells primarily to hospitals through a direct sales force. About 96% of 2023 sales came from territories with direct representatives; biologic products represented 51% of sales, and no product line exceeded 20% of revenue.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change / context |
|---|---|---|---|
| Net sales | $193.5 million | $161.7 million | +20% |
| Gross profit / margin | $127.0 million / 65.7% | $104.9 million / 64.9% | Gross profit +21%; margin +0.8 percentage points |
| Operating income / margin | $36.7 million / 19.0% | $26.8 million / 16.6% | Operating income +37% |
| Net income / margin | $30.1 million / 15.6% | $20.6 million / 12.8% | Net income +46% |
| Diluted EPS | $1.34 | $0.93 | +44% |
| Operating cash flow | $36.8 million | $25.4 million | Up $11.4 million; working capital used $11.3 million in 2023 |
| Cash and cash equivalents | $24.3 million | $19.1 million | At year-end |
| Short-term marketable securities | $80.8 million | $63.6 million | At year-end; 2023 unrealized loss was $1.2 million |
| Debt | No outstanding borrowings | No outstanding borrowings | Credit facility terminated in 2021; lease liabilities were $19.1 million at year-end 2023 |
Current assets were $194.6 million and current liabilities $29.9 million at year-end 2023. Cash flow used in investing was $24.7 million, including $16.6 million of marketable-security purchases and $7.3 million of capital expenditures. Financing used $7.1 million, including $12.4 million of dividends, partly offset by stock-option proceeds.
In Q4 2023, net sales were $48.9 million, gross profit $33.3 million, operating income $10.2 million, net income $8.5 million and diluted EPS $0.38. The comparable Q4 2022 figures were $41.0 million, $26.1 million, $7.0 million, $5.6 million and $0.25, respectively.
Material changes versus prior periods
- Annual sales growth was driven by higher average selling prices, increased hospital procedure volumes, additional sales representatives and $4.1 million of sales from a porcine cardiovascular patch distribution arrangement. Product increases included valvulotomes ($6.3 million), bovine vascular patches ($4.6 million), bovine grafts ($4.2 million), allograft services ($3.7 million) and carotid shunts ($3.1 million).
- Gross margin improved on favorable product mix and manufacturing efficiencies, partly offset by higher scrap and excess/obsolete inventory charges.
- Sales and marketing expense rose 25% to $41.1 million and R&D expense rose 28% to $17.0 million, reflecting staffing, commissions, testing and regulatory work. G&A rose 11% to $31.8 million. Restructuring expense declined to $0.5 million from $3.1 million, primarily relating to the St. Etienne factory closure.
- Sales increased across all regions: Americas +19%, Europe, Middle East and Africa +22%, and Asia Pacific +17%. International markets accounted for 39% of sales.
Outlook, management commentary, risks and unusual items
- Management did not provide a numerical 2024 sales or earnings forecast in the supplied filing text. It expects cash, investments and related interest income to cover anticipated cash needs for at least the next 12 months and known long-term needs.
- Planned initiatives include a U.S. limited market release of the next-generation PhasTIPP device in the first half of 2024; marketing Burlington-made CardioCel and VascuCel in the U.S., Canada and parts of Asia Pacific in the first half of 2024; and continued regulatory submissions. Management expects EU MDR approval for Burlington-made CardioCel/VascuCel in approximately 18–24 months and does not anticipate Artegraft EU market approval before the second half of 2025.
- The MDR transition is a significant regulatory risk: products require new CE marks under more stringent rules. Failure or delay could affect European sales. Anteris is expected to supply CardioCel and VascuCel through January 2025 while the Burlington manufacturing transition and approvals proceed.
- The company began implementing a new ERP system in February 2024. Implementation delays, cost overruns or operational/control problems could disrupt orders, manufacturing, reporting or internal controls; $3.6 million of implementation costs had been capitalized at year-end 2023. Management reported effective disclosure controls and internal control over financial reporting at December 31, 2023; the ERP was not yet in service.
- Other key exposures include competition and a shift from open surgery toward minimally invasive procedures (over 95% of 2023 sales were from devices used in open surgery), pricing and reimbursement pressure, reliance on limited-source suppliers and tissue procurement, foreign exchange, international regulatory requirements, and acquisition integration. Management also cites potential long-term market effects from GLP-1 drugs.
- During 2023, the company reported one Class II recall in Europe related to a manufacturing process and one Class 3 U.S. recall related to a supply process; neither involved patient injury. Management said no pending legal matters were expected to have a material adverse financial effect.
- After year-end, the board authorized a share repurchase program of up to $50 million through February 21, 2025; no repurchases had been made under it as of the filing. The quarterly dividend was raised to $0.16 per share in February 2024, subject to board approval for future dividends.
Most important facts for investors to verify
- Whether 2024 sales growth and margins persist as pricing, product mix and manufacturing efficiencies evolve alongside rising sales, R&D and selling costs.
- Progress and timing of MDR/UKCA approvals, especially CardioCel, VascuCel and Artegraft, and continuity of Anteris supply through the planned transition.
- ERP implementation progress, including any cost changes, operational disruption or effects on financial reporting controls.
- Inventory growth and working-capital conversion: inventory and other deferred costs reached $58.1 million, up from $50.3 million, while 2023 operating cash flow included substantial working-capital use.
- Execution of the $50 million repurchase authorization and sustainability of dividends, considering cash needs for investment, acquisitions and regulatory programs.
- Exposure to foreign exchange, European customer payment delays, limited-source suppliers and the continuing shift toward endovascular procedures.
The independent auditor issued an unqualified opinion on the 2023 financial statements and internal control over financial reporting; it reported no critical audit matters.